HighTide Therapeutics’ HTD1801 Shows Promising Results in Phase 3 Trials for Type 2 Diabetes

Hightide Therapeutics Inc ( (HK:2511) ) has shared an announcement.

HighTide Therapeutics announced that their lead compound, HTD1801, met the primary endpoints in two Phase 3 clinical trials for patients with type 2 diabetes mellitus. The trials, named SYMPHONY 1 and SYMPHONY 2, demonstrated significant glucose-lowering effects and improvements in cardiometabolic risk indicators. Based on these results, HighTide plans to submit a new drug application for HTD1801 in China. The trials also showed favorable safety and tolerability profiles, with minimal adverse events reported.

More about Hightide Therapeutics Inc

HighTide Therapeutics, Inc. is a company incorporated in the Cayman Islands, focusing on the development of innovative therapies for metabolic and digestive diseases. Their primary product is HTD1801, a gut-liver anti-inflammatory metabolic modulator, which is being developed for multiple indications including type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatohepatitis (MASH).

YTD Price Performance: 11.81%

Average Trading Volume: 1,015,966

Technical Sentiment Signal: Hold

Current Market Cap: HK$731M

See more insights into 2511 stock on TipRanks’ Stock Analysis page.